Adults receiving HIV care before the start of antiretroviral therapy in Sub-Saharan Africa: Patient outcomes and associated risk factors

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 5, 2013, Pages 455-463

  Bastard, Mathieu ^a   Nicolay, Nathalie ^a   Szumilin, Elisabeth ^b   Balkan, Suna ^b   Poulet, Elisabeth ^a   Pujades Rodriguez, Mar ^a,c  

^a Clinical Research Department   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adults; gender; HIV; lost to follow up; mortality; pre antiretroviral therapy

Indexed keywords

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; METHODOLOGY; PATIENT CARE; RISK FACTOR; TREATMENT OUTCOME; EPIDEMIOLOGY; HIV INFECTIONS; PROCEDURES; TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PATIENT CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891591562     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a61e8d     Document Type: Article

References (40)

1. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Med. 2007;4:e298. doi:10.1371/journal.pmed.0040298
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland: WHO Library, 2012. Available at: Http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120-UNAIDS- Global-Report-2012-en.pdf. Accessed May 5, 2013
3. Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa?.. not everyone who should. AIDS. 2010;24(suppl 1): S37-S44. doi:10.1097/01.aids.0000366081.91192.1c.
4. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: Implications for program evaluation. Clin Infect Dis. 2006;43:770-776. doi:10.1086/507095
5. Lessells RJ, Mutevedzi PC, Cooke GS, et al. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: Rural KwaZulu- Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56:e79-e86. doi:10.1097/QAI. 0b013e3182075ae2
6. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: A systematic review. PLoS Med. 2011;8:e1001056
7. doi:10.1371/journal.pmed.1001056
8. World Health Organization. Scaling up antiretroviral therapy in resource limited Settings: Guidelines for a public health approach. 2002. Available at: Http://apps.who.int/medicinedocs/en/d/Js2888e/. Accessed July 5, 2013
9. World Health Organization. Scaling up Antiretroviral Therapy in Resource- Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2003. Available at: Http://www.who.int/ 3by5/publications/documents/arv-guidelines/en/index.html. Accessed July 5, 2013
10. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach (2006 revision). 2006. Available at: Http://www.who.int/hiv/pub/arv/adult/en/.Accessed July 5, 2013
11. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. 2009. Available at: Http://www.who. int/hiv/pub/arv/advice/en/. Accessed July 5, 2013
12. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach. 2010 revision. Geneva, Switzerland: World Health Organization; 2010
13. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: A statistical analysis of 111 facilities in Africa, Asia, and Latin America. Bartlett J, ed. PLoS Med. 2011;8:e1001111. doi:10.1371/journal.pmed.1001111
14. Fine JP, Gray RJ. A proportional hazards model for the Subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509. doi:10.1080/01621459.1999. 10474144
15. Mugglin C, Estill J, Wandeler G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: Systematic review and meta-analysis. Trop Med Int Health. 2012;17: 1509-1520. doi:10.1111/j.1365-3156.2012.03089.x.
16. World Health Organization. Retention in HIV programmes: Defining the challenges and identifying solutions. Available at: Http://www.who.int/hiv/pub/ meetingreports/retention-programmes/en/. Accessed July 15, 2013
17. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290. doi:10.1186/1471-2458-9-290
18. Togun T, Peterson I, Jaffar S, et al. Pre-treatment mortality and loss-tofollow- up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res Ther. 2011;8:24. doi:10.1186/1742-6405-8-24
19. McGuire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health. 2010;15(suppl 1):55-62. doi:10.1111/j.1365-3156.2010.02504.x.
20. Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One. 2010;5:e13268. doi:10.1371/journal.pone.0013268
21. Hassan AS, Fielding KL, Thuo NM, et al. Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: A cohort study. Trop Med Int Health. 2012;17:82-93. doi:10.1111/j.1365-3156.2011.02889.x.
22. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: Systematic review and meta-analysis. PLoS One. 2009; 4:e5790. doi:10.1371/journal.pone.0005790
23. Lawn SD, Myer L, Bekker L-G, et al. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006; 6:59. doi:10.1186/1471-2334-6-59
24. Bekker L-G, Myer L, Orrell C, et al. Rapid scale-up of a communitybased HIV treatment service: Programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315-320. Available at: Http://www.ncbi.nlm.nih.gov/pubmed/16670804. Accessed April 23, 2013
25. Faal M, Naidoo N, Glencross DK, et al. Providing immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immune Defic Syndr. 2011;58:e54-e59. doi:10.1097/QAI.0b013e3182303921
26. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: An observational cohort study. Lancet. 2011; 378:1572-1579. doi:10.1016/S0140-6736(11)61052-0
27. Losina E, Bassett IV, Giddy J, et al. The "ART" of linkage: Pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010;5:e9538. doi:10.1371/journal.pone.0009538
28. Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681-688. doi:10.2471/BLT.09.064329
29. Larson BA, Brennan A, McNamara L, et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15(suppl 1):43-47. doi:10./j.1365-3156.2010. 02511.x.
30. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: Can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010;104:313-319. doi:10.1016/j.trstmh. 2010.01.007
31. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS. 1999;13:2361-2364. Available at: Http://www.ncbi.nlm. nih.gov/pubmed/10597777. Accessed July 15, 2013
32. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14:722-731. doi:10.1111/j.1365- 3156.2009.02290.x.
33. Kranzer K, Zeinecker J, Ginsberg P, et al. Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One. 2010;5: E13801. doi:10.1371/journal.pone.0013801
34. Chen SC-C, Yu JK-L, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13:513-519. doi:10.1111/j.1365- 3156.2008.02029.x.
35. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908. doi:10.1097/QAD.0b013e32830007cd.
36. DeSilva MB, Merry SP, Fischer PR, et al. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care. 2009;21:70-77. doi:10.1080/09540120802017636
37. MacPherson P, Moshabela M, Martinson N, et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg. 2009;103:588-593. doi:10.1016/j.trstmh.2008.10.001
38. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health. 2009;14:713-721. doi:10.1111/j.1365-3156.2009.02291.x.
39. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: A multicentre cohort study. PLoS Med. 2012;9:e1001304. doi: 10.1371/journal.pmed. 1001304
40. Hawkins C, Chalamilla G, Okuma J, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS. 2011;25:1189-1197. doi:10.1097/QAD.0b013e3283471deb